39325788|t|Abeta25-35-induced autophagy and apoptosis are prevented by the CRMP2-derived peptide ST2-104 (R9-CBD3) via a CaMKKbeta/AMPK/mTOR signaling hub.
39325788|a|We previously reported that the peptide ST2-104 (CBD3, for Ca2+ channel-binding domain 3), derived from the collapsin response mediator protein 2 (CRMP2)-a cytosolic phosphoprotein, protects neuroblastoma cells against beta-amyloid (Abeta) peptide-mediated toxicity through engagement of a phosphorylated CRMP2/NMDAR pathway. Abnormal aggregation of Abeta peptides (e.g., Abeta25-35) leads to programmed cell death (apoptosis) as well autophagy-both of which contribute to Alzheimer's disease (AD) progression. Here, we asked if ST2-104 affects apoptosis and autophagy in SH-SY5Y neuroblastoma challenged with the toxic Abeta25-35 peptide and subsequently mapped the downstream signaling pathways involved. ST2-104 protected SH-SY5Y cells from death following Abeta25-35 peptide challenge by reducing apoptosis and autophagy as well as limiting excessive calcium entry. Cytotoxicity of SHY-SY5Y cells challenged with Abeta25-35 peptide was blunted by ST2-104. The autophagy activator Rapamycin blunted the anti-apoptotic activity of ST2-104. ST2-104 reversed Abeta25-35-induced apoptosis via inhibiting Ca2+/CaM-dependent protein kinase kinase beta (CaMKKbeta)-mediated autophagy, which was partly enhanced by STO-609 (an inhibitor of CaMKKbeta). ST2-104 attenuated neuronal apoptosis by inhibiting autophagy through a CaMKKbeta/AMPK/mTOR signaling hub. These findings identify a mechanism whereby, in the face of Abeta25-35, the concerted actions of ST2-104 leads to a reduction in intracellular calcium overload and inhibition of the CaMKKbeta/AMPK/mTOR pathway resulting in attenuation of autophagy and cellular apoptosis. These findings define a mechanistic framework for how ST2-104 transduces "outside" (calcium channels) to "inside" signaling (CaMKKbeta/AMPK/mTOR) to confer neuroprotection in AD.
39325788	64	69	CRMP2	Gene	1808
39325788	86	93	ST2-104	Chemical	-
39325788	95	102	R9-CBD3	Chemical	-
39325788	110	119	CaMKKbeta	Gene	10645
39325788	120	124	AMPK	Gene	5564
39325788	125	129	mTOR	Gene	2475
39325788	185	192	ST2-104	Chemical	-
39325788	194	198	CBD3	Chemical	-
39325788	204	208	Ca2+	Gene	760
39325788	253	290	collapsin response mediator protein 2	Gene	1808
39325788	292	297	CRMP2	Gene	1808
39325788	336	349	neuroblastoma	Disease	MESH:D009447
39325788	364	392	beta-amyloid (Abeta) peptide	Chemical	-
39325788	402	410	toxicity	Disease	MESH:D064420
39325788	450	455	CRMP2	Gene	1808
39325788	618	637	Alzheimer's disease	Disease	MESH:D000544
39325788	639	641	AD	Disease	MESH:D000544
39325788	717	738	SH-SY5Y neuroblastoma	CellLine	CVCL:0019
39325788	765	783	Abeta25-35 peptide	Chemical	-
39325788	870	877	SH-SY5Y	CellLine	CVCL:0019
39325788	905	923	Abeta25-35 peptide	Chemical	-
39325788	1000	1007	calcium	Chemical	MESH:D002118
39325788	1015	1027	Cytotoxicity	Disease	MESH:D064420
39325788	1031	1039	SHY-SY5Y	CellLine	CVCL:E828
39325788	1062	1080	Abeta25-35 peptide	Chemical	-
39325788	1129	1138	Rapamycin	Chemical	MESH:D020123
39325788	1178	1185	ST2-104	CellLine	CVCL:2205
39325788	1187	1194	ST2-104	Chemical	-
39325788	1248	1252	Ca2+	Gene	760
39325788	1295	1304	CaMKKbeta	Gene	10645
39325788	1355	1362	STO-609	Chemical	MESH:C458525
39325788	1380	1389	CaMKKbeta	Gene	10645
39325788	1411	1429	neuronal apoptosis	Disease	MESH:D065703
39325788	1464	1473	CaMKKbeta	Gene	10645
39325788	1474	1478	AMPK	Gene	5564
39325788	1479	1483	mTOR	Gene	2475
39325788	1596	1603	ST2-104	Chemical	-
39325788	1642	1649	calcium	Chemical	MESH:D002118
39325788	1681	1690	CaMKKbeta	Gene	10645
39325788	1691	1695	AMPK	Gene	5564
39325788	1696	1700	mTOR	Gene	2475
39325788	1896	1905	CaMKKbeta	Gene	10645
39325788	1906	1910	AMPK	Gene	5564
39325788	1911	1915	mTOR	Gene	2475
39325788	1946	1948	AD	Disease	MESH:D000544
39325788	Negative_Correlation	MESH:C458525	10645
39325788	Association	MESH:D009447	1808
39325788	Association	MESH:D064420	1808

